SESN Sesen Bio Inc.

1.44
-0.04  -3%
Previous Close 1.48
Open 1.48
Price To Book 3.05
Market Cap 115,897,461
Shares 80,764,781
Volume 228,562
Short Ratio
Av. Daily Volume 3,970,383

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Rolling BLA filing to commence 4Q 2019.
Vicinium
Non-muscle invasive bladder cancer (NMIBC)

Latest News

  1. The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut
  2. Sesen Bio Announces Proposed Public Offering of Common Stock and Warrants
  3. Sesen Bio Announces Successful Pre-BLA Meeting with FDA for Vicinium®
  4. Edited Transcript of SESN earnings conference call or presentation 13-May-19 12:00pm GMT
  5. Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Regulatory Update on Pre-BLA Meeting for Vicinium®
  6. Penny Stocks to Buy Using Technical Analysis for June 2019
  7. Sesen Bio Announces Acceptance of Analytical Comparability Plan by the U.S. Food and Drug Administration to Support the BLA and Commercialization of Its Lead Asset, Vicinium® for Non-Muscle Invasive Bladder Cancer
  8. Options Traders Expect Huge Moves in Sesen Bio (SESN) Stock
  9. Sesen Bio Reports First Quarter 2019 Financial Results and Updated, Preliminary Primary and Additional Secondary Endpoint Data from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer
  10. Will the Good News for Vicinium Continue for Sesen Bio, They Will Tell Investors Soon
  11. Sesen Bio to Host Conference Call to Review First Quarter 2019 Financial Results and Updated Preliminary Data from Phase 3 VISTA Trial
  12. Four Healthcare Stocks Getting a Boost on Thursday
  13. Positive Results and New Technology Give Rise to Antibody Dominance
  14. Edited Transcript of SESN earnings conference call or presentation 4-Mar-19 1:00pm GMT
  15. What Kind Of Shareholder Owns Most Sesen Bio, Inc. (NASDAQ:SESN) Stock?
  16. Sesen Bio Reports Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial
  17. Sesen Bio to Host Conference Call to Review Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial
  18. Health Stocks Benefitting the Most from Rally
  19. Sesen Bio, Inc. (NASDAQ:SESN): A Fundamentally Attractive Investment
  20. Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer